Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

First Tracks Biotherapeutics, Inc. (TRAX)

Healthcare Biotechnology
44.00 $
-7.8% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at First Tracks Biotherapeutics, Inc..

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 4 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap
0.0$B
Shares Outstanding
35Mio.
Float
89.0%
Beta

Performance

Perf. 1M
7.50%
Perf. 3M
29.70%
Perf. 6M
YTD Performance (%)
52-Week-High Distance
-38.9%
Perf. 5Y
31.73%

Valuation

P/E
Forward P/E
0.0
PEG
P/B
2.3
P/S
EV/EBITDA
0.0
Price/FCF

Profitability

Gross Margin
EBIT Margin
Net Margin
0.0%
Return on Equity
-48.9%
Return on Assets
-29.0%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
Altman Z″
Piotroski

Growth

Sales Growth Last Quarter
0.00%
EPS Growth Last Quarter
Sales Growth (Year)
Forward Sales Growth
0.00%
Forward EPS Growth
12.90%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
2
RS Rating
63
EPS Rating
50
Piotroski
Fundamental Rating
D (28 out of 100)
Altman Z″

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Analysts & Price Target

Current Price 44.00 $
Price Target (average) 38.13 $

The price target sits 13.3% below the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

11. Aug 2026 · Q2 2026
Expected Earnings per Share
-0.74 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Sales Per Quarter ($M)
2025: Q1 · 0.0 $M Q1 2026: Q1 · 0.0 $M Q1
Earnings Per Share Per Quarter ($)
2025: Q1 · -1.36 $ Q1 2026: Q1 · -1.45 $ Q1
Operating Cash Flow Per Quarter ($M)
2025: Q1 · -45.0 $M Q1 2026: Q1 · -32.6 $M Q1
Free Cash Flow Per Quarter ($M)
2025: Q1 · -45.0 $M Q1 2026: Q1 · -32.6 $M Q1

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2025: Q1 -1.36 0 -45 -45
2026: Q1 -1.45 0 -33 -33
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

First Tracks Biotherapeutics, Inc. betreibt ein Biotechnologieunternehmen in der klinischen Phase mit Fokus auf der Bereitstellung immunologischer Therapeutika für Autoimmun- und Entzündungserkrankungen in den USA.

Employees104
HeadquartersSan Diego, CA
Websitefirsttracksbio.com
IPO Date20. Apr 2026

Management

Management
Name Title Birth Year
Daniel R. Faga CEO, President & Director 1980
Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. Chief Medical Officer 1975
Ajim A. Tamboli C.F.A. Chief Financial Officer 1977
Benjamin Stone Chief Business Officer 1991
Eric J. Loumeau Secretary 1963

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?